Aspire Biopharma Holdings, Inc. (ASBP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 61/100 (HIGH), 20.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.13% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program
- Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.
- EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal
- OTC Markets Life Sciences Investor Forum: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR’s David Bautz, PhD
- Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th
- ASBP Stock Heads For Best Week In Over 2 Months – Why This Drug Delivery Tech Firm Is Buying An Auto Supplier?
- Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
- Aspire Biopharma Issues Shareholder Letter
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Aspire Biopharma Holdings, Inc..
Full ASBP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.